∙ Pre-procedural:

• Participant has signed and dated informed consent, is capable of understanding the nature, significance and implications of the clinical trial, and is willing to comply with all study procedures and follow-up visits for the duration of the study.

• Participant is male or female, aged 18 years or older.

• If participant is female and of reproductive potential: agreement to use a highly effective contraception (abstinence is acceptable) for at least 90 days after study treatment.

• Participant has severe claudication (Rutherford 3) or chronic limb-threatening ischemia (CLTI) (Rutherford 4-5) in the Target Limb.

• Angiographic/Procedural:

• Participant has up to two de novo or restenotic Qualified Target Lesions meeting the following criteria, each based on the Investigator's visual assessment. Target Lesions should be considered separate if they are located in separate vessels (not in the same blood path) or have more than 10 cm intervening normal artery.

• Diameter

⁃ ≥70% diameter stenosis anywhere within the Target Lesion or ≥50% diameter stenosis spanning at least 10 cm of length.

⁃ Reference (normal) vessel diameter ≥2 mm and ≤8 mm. Location

⁃ Any lesion chosen as a Target Lesion is in or spans at least one below-knee popliteal (P3 segment), tibial, or peroneal artery and is a culprit for dominant disease symptoms based on Investigator's assessment.

⁃ ≥50% of the Target Lesion length is below the knee joint space (\<50% of Target Lesion length may extend above the midline of the knee joint space).

⁃ ≥10 mm away from any previously placed stent or graft.

⁃ A Target Lesion may cross an ostium of another artery (i.e. pass a bifurcation) but may only include one of the two branches. (Notes: Investigator should choose the dominant lesion for Target Lesion. Bifurcated lesions should be excluded, but if a lesion in a bifurcating vessel is separate from a Target Lesion based on intervening normal artery from which a proximal reference diameter can be measured, it may be treated as a second Target Lesion.) Length

⁃ ≤30 cm in cumulative length from most proximal to most distal normal segment bounding the Target Lesion(s).

⁃ A single Target Lesion may be comprised of multiple lesions or multifocal lesions (i.e. tandem lesions) if there is no continuous normal segment \>10cm in length within the Target Lesion.

⁃ Target Lesion may be in a vessel with another Target Lesion or above-knee non-target lesion if it is \>10 cm away.

• Participant receives successful revascularization, based on the following Investigator visual assessments:

‣ Target Lesion and any treated non-target lesion in a Target Vessel or its inflow has \<30% residual stenosis, outflow has \<50% stenosis, and there is no flow-limiting dissection or perforation after treatment in an inflow vessel or Target Vessel.

⁃ Participant has distal run-off into the foot with a patent named pedal artery.